Tag: Xeltis

Xeltis presents six-month first-in-human data on aXess graft

Xeltis has presented “highly-encouraging” six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society (VAS;...

Xeltis secures funding to progress clinical trials

Xeltis has raised €32 million in a Series D2 equity fundraise, backed by a syndicate of current and new investors, which the company says...
top 10

Vascular News’ top 10 most popular stories of November 2022

November's top 10 includes the first results from BEST-CLI, as well as new data presented at this year's Vascular Interventional Advances (VIVA; 31 October–3...

Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access...

Xeltis announced today the initiation of a pivotal trial with the “first-ever” restorative synthetic haemodialysis access graft, dubbed ‘Axess’. The first two patients have been...

Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft

Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a...

Restorative Axess graft demonstrates promising patency and safety in first-in-human study

The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...